Department of Vermont Health Access
Pharmacy Benefits Management Program
**DUR Board Meeting Agenda**

**June 26, 2012  6:30 – 9:00 p.m.**

1. **Executive Session  6:30 - 7:00**
   - Discussion on Medicaid OBRA'90/Supplemental Rebates and Agreements
     (as provided by 33 VSA § 1998(f)(2))

2. **Introductions and Approval of DUR Board Minutes  7:00 - 7:05**
   (Public Comment Prior to Board Action)

3. **Election of DUR Board Chair  7:05-7:15**
   (call for nominations and election)

4. **DVHA Pharmacy Administration Updates  7:15 - 7:25**
   - Updates
   - Prescribed Product Disclosures: Report for Fiscal Year 2011

5. **Medical Director Update  7:25 - 7:30**
   - Clinical Programs Update
   - Prescriber Comments

6. **Follow-up Items from Previous Meetings  7:30 - 7:45**
   - Xifaxan® in Hepatic Encephalopathy
   - Atypical Antipsychotics – Pediatric Use
   - Letter to Prescribers regarding Days’ Supply and Early Refill
   - Pharmacy Newsletter

7. **RetroDUR/DUR  7:45 – 7:45**
   - None

8. **Clinical Update: Drug Reviews  7:45 – 8:00**
   (Public comment prior to Board action)

   **Abbreviated New Drug Reviews**
   - Duexis® (famotidine/ibuprofen) Oral Tablet
   - Opana® ER (oxymorphone ER) (Crush Resistant Formulation)

   **Full New Drug Reviews**
   - Kalydeco® (ivacaftor) Oral Tablet
9. **Therapeutic Drug Classes – Periodic Review**  
   8:00 – 8:20  
   (Public comment prior to Board action)  
   Class review documents available on DVHA web site 6/26/2012 @ 12 Noon  
   - Anticoagulants  
     - Injectable  
     - Oral  
   - DPP-4 Inhibitors and Combinations (includes review of Janumet XR®, Jentadueto®)  
   - Hereditary Angioedema Agents

10. **New Managed Therapeutic Drug Classes**  
    8:20 – 8:20  
    (Public comment prior to Board action)  
    - None

11. **Review of Newly-Developed/Revised Clinical Coverage Criteria and/or Preferred Products**  
    8:20 – 8:50  
    (Public comment prior to Board action)  
    - Anti-hyperkinesis and Anti-Narcolepsy: ADHD (quantity limits)  
    - Multiple Sclerosis Medications (new information Gilenya® and Tysabri®)  
    - Nutritional Products

12. **General Announcements**  
    8:50– 9:00  
    Selected FDA Safety Alerts  
    - Aliskiren-Market withdrawal of Valturna®  
    - Tysabri® - Drug Safety Communication – Update of Risk Factors for PML

13. **Adjourn**  
    9:00